CN Patent

CN114634521A — Dna-pk选择性抑制剂及其制备方法和用途

Assigned to Capital Pharmaceutical Holdings Beijing Co ltd · Expires 2022-06-17 · 4y expired

What this patent protects

本申请涉及式(I)所示的一类DNA‑PK选择性抑制剂及其制备方法和用途。所述用途包括式(I)化合物在制备治疗跟DNA‑PK相关的疾病的药物中的用途。在制备过程中，通过取代、还原、成环、以及烷基化等一系列反应，得到本发明化合物。

USPTO Abstract

本申请涉及式(I)所示的一类DNA‑PK选择性抑制剂及其制备方法和用途。所述用途包括式(I)化合物在制备治疗跟DNA‑PK相关的疾病的药物中的用途。在制备过程中，通过取代、还原、成环、以及烷基化等一系列反应，得到本发明化合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN114634521A
Jurisdiction
CN
Classification
—
Expires
2022-06-17
Drug substance claim
No
Drug product claim
No
Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.